F3 and Disseminated intravascular coagulation: However, the thrombotic risks associated with rFVIIa may be theoretically increased in clinical situations when there is systemic (e.g. disseminated intravascular coagulation) or localized (atherosclerotic plaque) pathologic expression of tissue factor, and or circulating activated platelet microparticles [24].